Cargando…
Real-world effectiveness and safety of risankizumab in patients with plaque psoriasis in whom guselkumab failed recently: A multicenter retrospective study of switching within the interleukin-23 inhibitor class
Autores principales: | Bagit, Ahmed, Maliyar, Khalad, Georgakopoulos, Jorge R., Rankin, Brian, Rimke, Alexander, Mufti, Asfandyar, Le, Heather, Vender, Ronald, Prajapati, Vimal H., Yeung, Jensen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319311/ https://www.ncbi.nlm.nih.gov/pubmed/37409313 http://dx.doi.org/10.1016/j.jdin.2023.05.006 |
Ejemplares similares
-
Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study
por: Lytvyn, Yuliya, et al.
Publicado: (2021) -
Use of risankizumab in two HIV-positive patients with psoriasis
por: Maliyar, Khalad, et al.
Publicado: (2023) -
Drug survival of guselkumab in patients with plaque psoriasis: A 2 year retrospective, multicenter study
por: Lytvyn, Yuliya, et al.
Publicado: (2021) -
Hydroxychloroquine effects on psoriasis: A systematic review and a cautionary note for COVID-19 treatment
por: Sachdeva, Muskaan, et al.
Publicado: (2020) -
Treatment outcomes of biologics and small molecules for chronic hand eczema: An evidence-based systematic review
por: Sood, Siddhartha, et al.
Publicado: (2023)